CRANFORD, N.J., Feb. 10, 2020 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a
specialty pharmaceutical company focused on adjunctive cancer care
and critical care drug products, announced today that the Company
will present at Noble Capital Markets' 16th Annual Investor
Conference on Monday, February 17,
2020 at 4:00 PM ET. The
conference is being held at the Seminole Hard Rock Hotel &
Casino in Hollywood, Florida on
February 16-18, 2020.
Event: Noble Capital
Markets' 16th Annual Investor Conference
Presentation Date:
Monday, February 17, 2020
Presentation Time:
4:00 PM ET – Terrace Ballroom A
Location: Seminole Hard
Rock Hotel & Casino – Hollywood,
FL
Mr. Leonard Mazur, Chairman of
Citius, will deliver an update on the Company, including a
discussion of the recent positive outcome of its interim futility
analysis for the Phase 3 Mino-Lok® pivotal trial, and provide an
overview of its other pipeline products, Mino-Wrap™ and Halo-Lido.
Additionally, Mr. Mazur will also be available at the conference
for one-on-one meetings with investors. To arrange a meeting
with the Company, please contact Mr. Andrew
Scott: ascott@citiuspharma.com.
Mr. Mazur's presentation will be available for playback at the
link below approximately 24 hours following his live address and be
archived for 90 days following the conference:
http://noble.mediasite.com/Mediasite/Play/838b6f0a3a53473cbd89e1507a111a411d
This is the 16th year Noble Capital Markets has
hosted "NobleCon" and invited emerging growth companies to present
to and meet with attending investors. NobleCon will feature
approximately 125 small growth companies presenting across four
tracks occurring simultaneously, company executives meeting with
investors in 1x1/face-to-face formats, and special panel sessions
featuring key opinion leaders on topics such as cannabis,
biotechnology, and mining, just to name a few. Noble Capital
Markets will be broadening access to investors worldwide by hosting
the conference site on Channelchek.com, its web-based market
platform that emphasizes emerging growth companies.
About Citius Pharmaceuticals, Inc.
Citius is a
specialty pharmaceutical company dedicated to the development and
commercialization of critical care products, with a focus on
anti-infectives, cancer care, and unique prescription products that
use innovative, patented, or proprietary formulations of
previously-approved active pharmaceutical ingredients. We seek to
achieve leading market positions by providing therapeutic products
that address unmet medical needs. By using previously
approved drugs with substantial safety and efficacy data, we seek
to reduce the risks associated with pharmaceutical product
development and regulatory requirements. Citius develops products
that have intellectual property protection and competitive
advantages to existing therapeutic approaches. For more
information, please visit www.citiuspharma.com.
Safe Harbor
This press release may contain
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements are made based on our
expectations and beliefs concerning future events impacting Citius.
You can identify these statements by the fact that they use words
such as "will," "anticipate," "estimate," "expect," "should," and
"may" and other words and terms of similar meaning or use of future
dates. Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual
results to differ materially from those currently anticipated are:
risks associated with conducting our Phase 3 trial for Mino-Lok,
including completing patient enrollment, opening study sites and
achieving the required number of catheter failure events; the
estimated markets for our product candidates and the acceptance
thereof by any market; our need for substantial additional funds;
risks associated with developing Mino-Wrap, including that
preclinical results may not be predictive of clinical results and
our ability to file an IND; risks related to our growth strategy;
our ability to identify, acquire, close and integrate product
candidates and companies successfully and on a timely basis; risks
relating to the results of research and development activities;
uncertainties relating to preclinical and clinical testing; the
early stage of products under development; our ability to obtain,
perform under and maintain financing and strategic agreements and
relationships; our ability to attract, integrate, and retain key
personnel; government regulation; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by
law.
Contact:
Andrew
Scott
Vice President, Corporate
Development
(O) 908-967-6677 x105
(M) 646-522-8410
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-noble-capital-markets-16th-annual-investor-conference-301001891.html
SOURCE Citius Pharmaceuticals, Inc.